Advisory Committee on Immunization Practices (ACIP), 79184-79185 [2020-27133]
Download as PDF
jbell on DSKJLSW7X2PROD with NOTICES
79184
Federal Register / Vol. 85, No. 237 / Wednesday, December 9, 2020 / Notices
Human Services (HHS), announces a
webinar entitled, ‘‘CDC STI Treatment
Guidelines Update’’. The purpose of the
webinar is for CDC to receive comments
from potential users on the proposed
updated guidelines. This webinar is an
opportunity for all interested parties to
ask questions and provide feedback, but
is specifically directed toward
clinicians, such as medical doctors,
nurse practitioners, and physician’s
assistants. CDC will consider comments
made during the webinar prior to
finalizing the updated STI Treatment
Guidelines for publication.
DATES: The webinar will be held on
December 18, 2020 from 2 p.m. to 4 p.m.
EST. Registration instructions can be
found on the website, https://
www.cdc.gov/std/treatment/default.htm.
ADDRESSES: The webinar will be
broadcast from the Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
Quinn Haaga, Public Health Advisor,
CDC, 1600 Clifton Road NE, MS–US 12–
2, Atlanta, GA 30329, stdtxguidelines@
cdc.gov.
SUPPLEMENTARY INFORMATION: The CDC’s
STI Treatment Guidelines Webinar is a
public presentation of proposed updates
to the CDC’s 2015 STD Treatment
Guidelines. The webinar will include
discussions of proposed changes to
CDC’s 2015 STD Treatment Guidelines
focusing on (1) changes to testing,
management, and/or treatment
recommendations for Neisseria
gonorrhoeae, Chlamydia trachomatis,
Trichomonas vaginalis treatment; (2)
role of metronidazole in pelvic
inflammatory disease treatment; (3)
alternative treatment options for
bacterial vaginosis; (4) management of
Mycoplasma genitalium; and (5) two
step testing for serologic diagnosis of
genital HSV2. Physicians and other
health-care providers can use these
guidelines to assist in the prevention
and treatment of STIs. Comments and
questions on the proposed changes may
be made during the webinar only.
Please refer to the posted agenda for
updates about the webinar one week
prior to the meeting. Information will be
provided on the following website when
it becomes available. https://
www.cdc.gov/std/treatment/default.htm.
A recording of the webinar and
accompanying transcripts will be
available by January 17, 2021 on the
website listed above. In addition, CDC’s
responses to questions from the webinar
will also be available February 15, 2021
on this website.
Participants must register by
December 17, 2020. This is a webinar-
VerDate Sep<11>2014
16:16 Dec 08, 2020
Jkt 253001
only event and there will be no on-site
participation at the CDC broadcast
facility.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2020–26974 Filed 12–8–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0122]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. The meeting will be webcast live
via the World Wide Web.
DATES: The meeting will be held on
December 11, 2020 from 12:00 p.m. to
5:00 p.m. EST and December 13, 2020
from 12:00 p.m. to 4:00 p.m. EST (times
subject to change, see the ACIP website
for any updates: https://www.cdc.gov/
vaccines/acip/).
Written comments must be received
on or before December 14, 2020.
ADDRESSES: For more information on
ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/
index.html.
You may submit comments, identified
by Docket No. CDC–2020–0122 by any
of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Docket No. CDC–2020–0122,
c/o Attn: December 11 and 13, 2020
ACIP Meeting, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, MS H24–8, Atlanta, GA
30329–4027.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 41 CFR 102–3.150(b),
less than 15 calendar days’ notice is
being given for this meeting due to the
exceptional circumstances of the
COVID–19 pandemic and rapidly
evolving COVID–19 vaccine
development and regulatory processes.
The Secretary of Health and Human
Services has determined that COVID–19
is a Public Health Emergency. A notice
of this ACIP meeting has also been
posted on CDC’s ACIP website at: https://
www.cdc.gov/vaccines/acip/.
In addition, CDC has sent notice of this
ACIP meeting by email to those who
subscribe to receive email updates about
ACIP.
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters To Be Considered: The agenda
will include discussions on COVID–19
vaccine. A recommendation vote(s) is
scheduled. Agenda items are subject to
change as priorities dictate. For more
information on the meeting agenda visit
https://www.cdc.gov/vaccines/acip/
meetings/meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
E:\FR\FM\09DEN1.SGM
09DEN1
79185
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 237 / Wednesday, December 9, 2020 / Notices
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials are part of
the public record and are subject to
public disclosure. Do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
CDC does not accept comment by email.
Written Public Comment: Written
comments must be received on or before
December 14, 2020. Oral Public
Comment: This meeting will include
time for members of the public to make
an oral comment. Oral public comment
will occur before any scheduled votes
including all votes relevant to the
ACIP’s Affordable Care Act and
Vaccines for Children Program roles.
Priority will be given to individuals
who submit a request to make an oral
public comment before the meeting
according to the procedures below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the December 13,
2020 ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
acip/meetings/ no later than 11:59 p.m.,
EST, December 11, 2020 according to
the instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by 12:00 p.m., EST, December 12, 2020.
To accommodate the significant interest
in participation in the oral public
comment session of ACIP meetings,
each speaker will be limited to 3
minutes, and each speaker may only
speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–27133 Filed 12–7–20; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
[OMB No. 0970–0234]
Proposed Information Collection
Activity; Social Services Block Grant
(SSBG) Post-Expenditure Report, PreExpenditure Report, and Intended Use
Plan
Office of Community Services,
Administration for Children and
Families, HHS.
ACTION: Request for Public Comment.
AGENCY:
The Administration for
Children and Families (ACF) is
requesting a revision to the Social
Services Block Grant (SSBG) PostExpenditure Report, Pre-Expenditure
Report, and Intended Use Plan (OMB
#0970–0234), previously titled, ‘‘Social
Services Block Grant (SSBG) PostExpenditure Report’’). ACF is proposing
to expand the information collection to
include the collection of states’
Intended Use Plans and retitle the
information collection to clarify the role
of the Pre-Expenditure Report.
DATES: Comments due within 60 days of
publication. In compliance with the
requirements of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
ACF is soliciting public comment on the
specific aspects of the information
collection described above.
ADDRESSES: Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
SUMMARY:
Administration for Children and
Families, Office of Planning, Research,
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: ACF
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: On an annual basis,
states and territories are required to
submit the following reports: (1) An
Intended Use Plan that provides data
and narrative descriptions related to the
state’s SSBG program. The Intended Use
Plan includes details about the delivery
of SSBG services and the state agency
administering the SSBG Program. ACF
is proposing to expand the currently
approved information collection to
include collection of states’ Intended
Use Plans. Grantees are required to
submit their Intended Use Plans no less
than 30 days prior to the start of the
budget period covered by the report. (2)
A Pre-Expenditure Report that
demonstrates the state’s anticipated
allocation of SSBG funding among the
29 pre-defined SSBG service categories.
Historically, states have submitted this
report using the Post-Expenditure
Report Form, and the associated burden
is included in the currently approved
information collection. Grantees are
required to submit their PreExpenditure Report no less than 30 days
prior to the start of the budget period
covered by the report. (3) A PostExpenditure Report that details the
state’s actual use of SSBG funding
among each of the 29 service categories.
Grantees are required to submit their
Post-Expenditure Report within 6
months of the end of the period covered
by the report.
Respondents: Agencies that
administer the SSBG at the state or
territory level, including the 50 states;
District of Columbia; Puerto Rico; and
the territories of American Samoa,
Guam, the Virgin Islands, and the
Commonwealth of Northern Mariana
Islands.
Annual Burden Estimates
This request is specific to the
Intended Use Plan. Currently approved
materials and associated burden can be
found at: https://www.reginfo.gov/
public/do/PRAViewICR?ref_nbr=
202011-0970-006.
Instrument
Annual number
of respondents
Annual number
of responses
per respondent
Average burden
hours per
response
Total/annual
burden hours
Intended Use Plan ...................................................................................
56
1
40
2,240
VerDate Sep<11>2014
16:16 Dec 08, 2020
Jkt 253001
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
E:\FR\FM\09DEN1.SGM
09DEN1
Agencies
[Federal Register Volume 85, Number 237 (Wednesday, December 9, 2020)]
[Notices]
[Pages 79184-79185]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-27133]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2020-0122]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. The meeting will be webcast
live via the World Wide Web.
DATES: The meeting will be held on December 11, 2020 from 12:00 p.m. to
5:00 p.m. EST and December 13, 2020 from 12:00 p.m. to 4:00 p.m. EST
(times subject to change, see the ACIP website for any updates: https://www.cdc.gov/vaccines/acip/).
Written comments must be received on or before December 14, 2020.
ADDRESSES: For more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
You may submit comments, identified by Docket No. CDC-2020-0122 by
any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Docket No. CDC-2020-0122, c/o Attn: December 11 and
13, 2020 ACIP Meeting, Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less
than 15 calendar days' notice is being given for this meeting due to
the exceptional circumstances of the COVID-19 pandemic and rapidly
evolving COVID-19 vaccine development and regulatory processes. The
Secretary of Health and Human Services has determined that COVID-19 is
a Public Health Emergency. A notice of this ACIP meeting has also been
posted on CDC's ACIP website at: https://www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by
email to those who subscribe to receive email updates about ACIP.
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the Director of the Centers for Disease Control and
Prevention and appear on CDC immunization schedules must be covered by
applicable health plans.
Matters To Be Considered: The agenda will include discussions on
COVID-19 vaccine. A recommendation vote(s) is scheduled. Agenda items
are subject to change as priorities dictate. For more information on
the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Meeting Information: The meeting will be webcast live via the World
Wide Web; for more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting
[[Page 79185]]
written views, recommendations, and data. Please note that comments
received, including attachments and other supporting materials are part
of the public record and are subject to public disclosure. Do not
include any information in your comment or supporting materials that
you consider confidential or inappropriate for public disclosure. If
you include your name, contact information, or other information that
identifies you in the body of your comments, that information will be
on public display. CDC will review all submissions and may choose to
redact, or withhold, submissions containing private or proprietary
information such as Social Security numbers, medical information,
inappropriate language, or duplicate/near duplicate examples of a mass-
mail campaign. CDC will carefully consider all comments submitted into
the docket. CDC does not accept comment by email.
Written Public Comment: Written comments must be received on or
before December 14, 2020. Oral Public Comment: This meeting will
include time for members of the public to make an oral comment. Oral
public comment will occur before any scheduled votes including all
votes relevant to the ACIP's Affordable Care Act and Vaccines for
Children Program roles. Priority will be given to individuals who
submit a request to make an oral public comment before the meeting
according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the December 13, 2020 ACIP meeting must
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ no later
than 11:59 p.m., EST, December 11, 2020 according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by 12:00 p.m., EST, December 12, 2020. To accommodate
the significant interest in participation in the oral public comment
session of ACIP meetings, each speaker will be limited to 3 minutes,
and each speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-27133 Filed 12-7-20; 4:15 pm]
BILLING CODE 4163-18-P